GI Innovation develops novel immunotherapies and allergy treatments using its GI-SMART™ platform, which employs high-throughput screening to identify and produce protein drug candidates. The company addresses the need for effective therapies in oncology and allergic diseases by leveraging advanced antibody technology to enhance target specificity and efficacy.
Funding
$143.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of novel immunotherapies and allergy treatments is hindered by the limitations of traditional drug discovery methods, which often struggle to efficiently identify and produce effective protein drug candidates with high specificity and efficacy. This challenge slows down the process of bringing new treatments to patients suffering from cancer and allergic diseases.
Solution
GI Innovation addresses this problem with its GI-SMART™ platform, a high-throughput screening system designed to identify and produce protein drug candidates. This platform enables the efficient screening of potential drug candidates and the production of stable cell lines for manufacturing. By integrating the GI-SMART™ platform with target antibody technology (GI-SMARTab™), GI Innovation optimizes the binding affinity, specificity, and physicochemical properties of dual-fusion proteins. This approach allows for the development of innovative therapies with enhanced efficacy and reduced off-target effects.
Target Audience
The primary target audience includes patients suffering from cancer and allergic diseases, as well as pharmaceutical companies seeking innovative drug candidates and advanced screening platforms.
Features
- GI-SMART™: A high-throughput screening system for identifying and producing protein drug candidates.
- GI-SMARTab™: Integrates the GI-SMART™ platform with target antibody technology to optimize dual-fusion proteins.
- Focus on immuno-oncology and allergic disease targets.
- Pipeline includes GI-101, GI-102, GI-10N (immuno-oncology), GI-301, and GI-30N (allergy and fibrosis), and GI-20N (metabolic disease).
- Development of macrophage engagers, such as GI-128, targeting PD-L1 and modulating macrophage activity.
- AI-driven clinical development strategies through collaboration with AI firms for optimized trial design and target discovery.